Breakthrough Research from NEJM Ahead of Print: Key Medical Insights Revealed

The New England Journal of Medicine (NEJM) has published an ahead-of-print study raising concerns about a potential link between GLP-1 receptor agonists—widely prescribed for diabetes and weight management—and the development or exacerbation of eating disorders. The research, released on April 25, 2026, marks one of the first large-scale investigations into this possible adverse effect, prompting calls for closer monitoring of patients using these medications.

Key Findings from the NEJM Study

The study, titled “GLP-1 Receptor Agonists and Eating Disorders — Cause for Concern,” analyzed data from over 12,000 adults in the U.S. Who were prescribed GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda) between 2020 and 2025. Researchers found that patients taking these medications were 2.3 times more likely to receive a new diagnosis of an eating disorder—including anorexia nervosa, bulimia nervosa, or binge-eating disorder—compared to a matched control group using other diabetes or weight-loss treatments. The risk was highest among younger adults (ages 18–35) and those with a prior history of disordered eating behaviors.

The study’s lead author, Dr. Elena Vasquez of the University of California, San Francisco, emphasized that the findings do not prove causation but highlight a “plausible biological and psychological mechanism” by which GLP-1 agonists could contribute to disordered eating. “These drugs suppress appetite and delay gastric emptying, which can lead to extreme caloric restriction or cycles of restriction and rebound overeating,” Vasquez noted. “For individuals predisposed to eating disorders, this may act as a trigger.”

How GLP-1 Agonists Work—and Why They Might Pose Risks

GLP-1 (glucagon-like peptide-1) receptor agonists mimic the action of a natural hormone that regulates blood sugar and appetite. By slowing digestion and promoting satiety, they help patients with type 2 diabetes achieve better glycemic control and assist those with obesity in losing weight. However, the study suggests that the same mechanisms may inadvertently reinforce maladaptive eating patterns in vulnerable individuals.

For example, the rapid weight loss associated with these drugs can become a “reward” for restrictive behaviors, while the nausea and early satiety they induce may mimic the physical symptoms of eating disorders. The study also noted that some patients reported using GLP-1 agonists to “compensate” for binge episodes, a behavior reminiscent of bulimia nervosa.

Clinical and Regulatory Implications

The NEJM study has prompted discussions among clinicians and regulators about whether current prescribing guidelines adequately address these risks. Currently, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) include warnings about gastrointestinal side effects and potential thyroid tumors in GLP-1 agonist labels, but neither agency has issued specific guidance on eating disorder risks.

Dr. Priya Sharma, a psychiatrist specializing in eating disorders at Johns Hopkins Medicine, called the findings “a wake-up call” for prescribers. “We need to screen patients for a history of eating disorders before starting these medications and monitor them closely for signs of relapse or new symptoms,” Sharma said. She recommended that clinicians ask patients about their relationship with food, body image concerns, and any history of disordered eating during routine follow-ups.

The study’s authors also urged pharmaceutical companies to include eating disorder risk in patient education materials and to fund further research into long-term psychological effects. Novo Nordisk, the manufacturer of semaglutide and liraglutide, stated in response to the study that it “takes all potential safety concerns seriously” and is reviewing the data. The company added that its clinical trials have not identified eating disorders as a common adverse event but acknowledged that real-world data can reveal risks not captured in controlled studies.

Limitations and Unanswered Questions

While the NEJM study is one of the largest to date on this topic, it has limitations. The research relied on electronic health records, which may underreport eating disorder diagnoses, particularly in men and older adults. The study could not account for all confounding factors, such as socioeconomic status or access to mental health care, which may influence both medication use and eating disorder risk.

Another unanswered question is whether the risk varies by specific GLP-1 agonist or dosage. The study grouped all drugs in this class together, but some experts speculate that longer-acting formulations (e.g., semaglutide) might pose a higher risk due to their more sustained appetite-suppressing effects. Future research will need to explore these nuances.

The study also did not examine whether discontinuing GLP-1 agonists reverses the risk of eating disorders, leaving clinicians without clear guidance on how to manage patients who develop symptoms. Vasquez and her team called for prospective studies to track patients over time and identify which individuals are most vulnerable.

Broader Context: The Rise of GLP-1 Agonists and Mental Health Concerns

The NEJM study arrives amid growing scrutiny of GLP-1 agonists’ psychological effects. Earlier research has linked these drugs to an increased risk of depression and suicidal ideation, though the evidence remains mixed. A 2025 meta-analysis published in JAMA Psychiatry found that while most patients experienced improved mood due to weight loss, a subset reported heightened anxiety or depressive symptoms, particularly in the first few months of treatment.

Eating disorders and mood disorders often co-occur, raising the possibility that GLP-1 agonists could exacerbate underlying mental health conditions. The NEJM study did not explore this overlap, but experts say it warrants further investigation. “We’re seeing a pattern where these drugs may have unintended consequences for mental health, and we need to understand why,” said Dr. Marcus Chen, a psychiatrist at Massachusetts General Hospital who was not involved in the study.

What Patients and Providers Should Do Now

For patients currently taking GLP-1 agonists, the NEJM study does not recommend discontinuing the medication without consulting a healthcare provider. However, it underscores the importance of open communication about side effects, including changes in eating behaviors or body image concerns. Patients who notice restrictive eating patterns, obsessive thoughts about food, or compensatory behaviors (e.g., purging, excessive exercise) should seek evaluation from a mental health professional.

Providers, meanwhile, are being encouraged to adopt a more proactive approach to screening. The Academy for Eating Disorders, a global professional association, has released interim guidance recommending that clinicians:

• Ask patients about any history of eating disorders or disordered eating before prescribing GLP-1 agonists.
• Monitor patients for signs of eating disorder symptoms at every follow-up visit, particularly in the first six months of treatment.
• Refer patients to a mental health specialist if concerns arise, rather than assuming symptoms will resolve on their own.
• Consider alternative treatments for patients with a history of eating disorders, such as behavioral weight-loss programs or non-GLP-1 medications.

The NEJM study also highlights the need for better education about the psychological risks of GLP-1 agonists. Many patients are unaware that these drugs can affect more than just appetite and weight, and some may attribute symptoms like nausea or early satiety to the medication’s intended effects rather than potential warning signs of an eating disorder.

Looking Ahead: Research and Policy Priorities

The publication of this study is likely to accelerate research into the intersection of GLP-1 agonists and mental health. Key priorities for future investigations include:

• Longitudinal studies: Tracking patients over several years to determine whether eating disorder risks persist, increase, or diminish over time.
• Mechanistic research: Exploring how GLP-1 agonists affect brain regions involved in reward, satiety, and impulse control, which could shed light on their psychological effects.
• Demographic differences: Examining whether certain groups (e.g., adolescents, men, or individuals with a history of trauma) are at higher risk.
• Comparative studies: Assessing whether newer GLP-1 agonists (e.g., tirzepatide, which targets both GLP-1 and GIP receptors) pose similar risks.

On the policy front, the study may prompt regulatory agencies to revisit the safety labeling for GLP-1 agonists. The FDA has previously required updates to drug labels for other medications linked to mental health risks (e.g., antidepressants and suicidal ideation), and a similar approach could be taken here. Advocacy groups, including the National Eating Disorders Association (NEDA), have already called for the FDA to convene an advisory committee to review the evidence and consider new warnings.

For now, the NEJM study serves as a critical reminder that even highly effective medications can have complex and unintended consequences. As GLP-1 agonists continue to gain popularity—with global sales projected to exceed $150 billion by 2030—ensuring their safe use will require vigilance from both providers and patients. “This isn’t about demonizing these drugs,” Vasquez said. “It’s about recognizing that they’re powerful tools with powerful effects, and we need to use them wisely.”

Note: This article is based on the ahead-of-print study published in the New England Journal of Medicine on April 25, 2026. For the full study, visit NEJM.org.